NY-THIRD-AVENUE-MGMT
26.2.2024 12:01:30 CET | Business Wire | Press release
Third Avenue Management LLC (“Third Avenue”), a New York City-based investment adviser and leading value investing firm, is pleased to announce the upcoming launch of the Third Avenue Global Value Fund (ISIN: IE000K2CIQ63)1. The Fund will run in parallel with Third Avenue’s flagship global value strategy and employ Third Avenue’s unique fundamental, bottom-up, value investing philosophy in publicly traded securities globally.
The global value strategy has been managed for more than three decades and, since its inception in 1990, has provided investors with attractive long-term returns. The Fund will be structured as a sub-fund of Ireland-domiciled UCITS, Gemini Investment Funds (Ireland) Plc2, and is the second UCITS fund offering from Third Avenue along with its highly regarded Third Avenue Real Estate Value Fund (ISIN: IE00B6WFK718).
“We are thrilled to offer the Third Avenue Global Value Fund to qualified non-US investors,” said Portfolio Manager Matthew Fine. “For more than three decades, Third Avenue has delivered attractive results using a unique balance sheet-focused, price-conscious, fundamental value philosophy, an approach that is arguably more uncommon today than at any point in many decades. We also believe it to be an excellent time to broaden the availability of our strategy to a wider investor base, given the rapidly growing investor interest in value strategies as an alternative to growth-oriented and index-based strategies.”
Third Avenue has partnered with Capital Strategies Partners, an independent third-party marketer headquartered in Madrid with a global presence that specializes in identifying talented managers for local distribution.
“We are excited about our partnership with Capital Strategies,” said Erik Kleinbeck, Managing Director and Head of Business Development at Third Avenue. “This relationship allows Third Avenue to focus on our core equity portfolio management expertise while leveraging the reach and scale of Capital Strategies’ 20 years of experience in client acquisition and retention in the asset management industry.”
“We are delighted to extend a warm welcome to Third Avenue as a valued Investment Manager. By launching the Global Value Fund as a UCITS vehicle, we hold firm in our confidence that Third Avenue’s resilient and proven methodology and track record will effectively cater to the needs of our investor base, spanning both institutional and wholesale segments,” said Daniel Rubio, Founder & CEO of Capital Strategies Partners.
“As a business that values our partnerships with Fund Managers in building strong investment propositions for investors, we at GemCap look forward to continuing our collaboration with Third Avenue to launch the Third Avenue Global Value Fund and work with Capital Strategies Partners to deliver this strategy to the broader UCITS fund investor community,” said Stuart Alexander, Director of Gemini Capital Management3.
About Third Avenue Management
Third Avenue Management LLC is a New York City-based investment adviser founded in 1986 by legendary investor Martin J. Whitman. For more than 35 years, the Firm has consistently pursued a value approach to investing by focusing on the company’s balance sheet, the value of its underlying assets, the discounted price of its securities, and the ability of the enterprise to increase its corporate net worth over time. Today, the Firm is partnered with AMG (NYSE: AMG) and has more than $1.4 billion in assets under management across its five core strategies – Global Value (Nasdaq: TAVFX), U.S. Small-Cap Value (Nasdaq: TASCX), Global Real Estate (Nasdaq: TAREX), International Real Estate (Nasdaq: REIFX), and International Value – which are available to investors through Mutual Funds, UCITS, Separate Accounts, and Sub-Advisory arrangements. For more information visit Third Avenue at www.thirdave.com.
_________________________
1 The launch of the Third Avenue Global Value Fund is subject to final regulatory approval of the Fund, expected around March 1, 2024
2 Gemini Investment Funds (Ireland) Plc is authorised by the Central Bank of Ireland (C67292)
3 Gemini Capital Management (Ireland) Ltd is authorised by the Central Bank of Ireland (C155302)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240226950474/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom